

## MATERIALS LICENSE

Amendment 13

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

## Licensee

1. V. A. Medical Center

2.

200 Springs Road  
Bedford, Massachusetts 01730In accordance with application dated  
April 30, 1985

3. License number 20-10184-01 is amended

in its entirety to read as follows:

4. Expiration date September 30, 1985

5. Docket or  
Reference No. 030-019276. Byproduct, source, and/or  
special nuclear material7. Chemical and/or physical  
form8. Maximum amount that licensee  
may possess at any one time  
under this licenseA. Any byproduct material  
listed in Groups I and  
II of Schedule A, Section  
35.100 of 10 CFR 35B. Any byproduct material  
listed in Group III of  
Schedule A, Section  
35.100 of 10 CFR 35C. Any byproduct material  
listed in Section 31.11(a)  
of 10 CFR 31

D. Hydrogen 3

E. Calcium 45

F. Carbon 14

G. Phosphorus 32

H. Sulfur 35

I. Iron 59

J. Iodine 131

K. Iodine 125

L. Chromium 51

M. Nickel 63

A. Any radiopharmaceutical  
listed in Groups I and  
II of Schedule A, Section  
35.100 of 10 CFR 35B. Any form listed in Group  
III of Schedule A, Section  
35.100 of 10 CFR 35

C. Prepackaged kits

D. Any

E. Any

F. Any

G. Any

H. Any

I. Any

J. Any

K. Any

L. Any

M. Foil in Varian Model  
01-001028-00 Detector  
CellA. As necessary for uses  
authorized in Subitem  
9.A.B. 2 curies of each  
byproduct material  
authorized in Subitem  
6.B.C. 10 millicuries of each  
byproduct material  
authorized in Subitem  
6.C.

D. 100 millicuries

E. 5 millicuries

F. 20 millicuries

G. 30 millicuries

H. 10 millicuries

I. 2 millicuries

J. 5 millicuries

K. 20 millicuries

L. 20 millicuries

M. 8 millicuries

## 9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. In vitro studies.D. through L. Laboratory research including animal studies.

M. To be used in a Varian Model 3700 gas chromatograph.

8507170650 B50625  
REQ1 LIC30  
20-10184-01

PDR

"OFFICIAL RECORD COPY"

ML10

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

20-10184-01

Docket or Reference number

030-01927

Amendment No. 13

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities, 200 Springs Road, Bedford, Massachusetts.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. A. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:
- |                               |   |
|-------------------------------|---|
| Dean J. Rodman, M.D.          | Groups I, II and III<br><u>In vitro</u> studies   |
| Walter V. Collins, M.D.       | Groups I, II and III<br><u>In vitro</u> studies   |
| Allan M. Green, M.D., Ph.D.   | Groups I, II and III<br><u>In vitro</u> studies   |
| Kalidas Nandy, M.D., Ph.D.    | <u>In vitro</u> studies<br>Subitems D. through M. |
| Choompol Mahasaen, M.D.       | <u>In vitro</u> studies<br>Subitems D. through M. |
| Ladislav Volicer, M.D., Ph.D. | <u>In vitro</u> studies<br>Subitems D. through M. |
| Victor N. Evdokimoff, M.S.    | <u>In vitro</u> studies<br>Subitems D. through M. |
| Vincent Agnello, M.D.         | <u>In vitro</u> studies<br>Subitems D. through M. |
| Carol Ann Toth, Ph.D.         | <u>In vitro</u> studies<br>Subitems D. through M. |
| Fredrick L. Moolten, M.D.     | <u>In vitro</u> studies<br>Subitems D. through L. |
| M. David Ullman, Ph.D.        | Subitems D., E., F., G., and H.                   |
| Deepak Pandya, M.D.           | Subitems D., E., F., and H.                       |
| Michael J. Malone, M.D.       | Subitems D., E., F., and H.                       |
- B. The Radiation Protection Officer for the activities authorized by this license is Choompol Mahasaen, M.D.

**MATERIALS LICENSE**  
SUPPLEMENTARY SHEET

License number

20-10184-01

Docket or Reference number

030-01927

Amendment No. 13

(continued)

**CONDITIONS**

14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
- (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
- (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for the inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

15. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
- B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
- C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

16. The licensee shall not use licensed material specified in Subitems C through M in or on human beings or any licensed materials in field applications where activity is released except as provided otherwise by specific condition of this license.

17. Detector cells containing licensed material shall not be opened or the foil sources removed from the detector cell by the licensee.

18. In lieu of using the conventional radiation caution colors (magenta or purple on yellow background) as provided in Section 20.203(a)(1), Title 10, Code of Federal Regulations, Part 20, the licensee is hereby authorized to label detector cells and cell baths, containing licensed material and used in gas chromatography devices, with conspicuously etched or stamped radiation caution symbols without a color requirement.

19. A. Each chromatograph detector containing Nickel 63 shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a detector received from another person shall not be put into use until tested.

**MATERIALS LICENSE**  
SUPPLEMENTARY SHEET

License number

20-10184-01

Docket or Reference number

030-01927

Amendment No. 13

(19. continued)

**CONDITIONS**

- C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the foil from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the test with the U.S. Nuclear Regulatory Commission, Region I, 631 Park Avenue, King of Prussia, Pennsylvania 19406, describing the equipment involved, the test results, and the corrective action taken.
- D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically authorized by the Commission or an Agreement State to perform such services.
20. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated March 30, 1979 and letters dated September 4, 1980, July 25, 1980, April 27, 1981, April 30, 1984, October 4, 1984 and January 14, 1985; application dated April 30, 1985 including ALARA Program; and letters dated May 7, 1985 and June 7, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Original Signed By:

Jenny M. Johansen

Date

JUN 25 1985

By

Nuclear Materials Safety and  
Safeguards Branch, Region I  
King of Prussia, Pennsylvania 19406